Bio-Techne Webinars
-
Navigating Challenges In Immune Cell Therapy Analysis
3/27/2024
During this panel, experts discuss the challenges faced by developers and manufacturers in the immune cell therapy field. These challenges include scalability, regulatory hurdles, and data standardization.
-
MultiTAA-Specific T Cells
3/27/2024
Learn about the MultiTAA T cell therapy approach, and discover how it has enhanced patient outcomes by targeting multiple antigens.
-
Removing The Barriers To Effective AAV Process Development
12/13/2022
Learn from an analytical scientist about the demand for efficiency in bioprocess workflows that is driving a need for greater improvements in analytical assay performance and instrument automation.
-
Quick, Accurate Testing For Lentivirus And AAVs
7/28/2022
Cell and gene therapies offer significant promise to treat life-threatening diseases, but getting therapies to market quickly and efficiently requires accurate testing of CQAs, including accurate viral vector analysis.
-
Modernize Your Gene Therapy Analytics With The Right Automated Tools
1/24/2022
Hear how a variety of innovative analytical tools can support your gene therapy workflow from discovery to quality control and how they can address certain critical quality attributes of your therapeutic.
-
Recombinant Antibody Technology: Versatile Platforms For Diverse Engineering And Custom Services
9/22/2021
Antibodies play a critical role in research, diagnostics and therapeutics. Recombinant antibodies offer a wide range of quality attributes, with one key advantage being their amenability to sequence-based editing to meet specific research goals. Learn about the latest developments in recombinant antibody technology including a platform where recombinant antibodies can be rapidly engineered into diverse formats and novel molecules such as immunocytokines or bispecific antibodies.
-
Natural Killer Cells Or Contaminant? Imaged Based Micro-Flow Imaging (MFI), Sub-Visible Particle Solution, For Cell Therapy
6/30/2021
Natural killer (NK) cell therapy is a rapid emerging field with several advantages over chimeric antigen receptor (CAR) T-cells for cancer treatment. Like any biotherapeutic drug, cell-based therapeutics must also undergo tight scrutiny for their critical quality attributes (CQAs). There are different criteria evaluated for drug purity, with the presence of visible and sub-visible particulate matter being one of them. Particulate impurities can affect drug efficacy and stability but can cause undesirable immunogenicity and toxicity when injected. In this webinar, we will showcase Micro-Flow Imaging (MFI) as a sub-visible particle analysis solution to differentiate NK cells and its expansion components with either irradiated K-562 feeder cells or Cloudz™ microspheres.
-
Development And Assessment Of Empty And Full AAVs
6/17/2021
Dr. Julie Wei discusses AAV empty and full separation using the icIEF method, showcasing how icIEF separates an AAV drug substance that could not be separated using other techniques.
-
How To Use Maurice To Characterize AAVs And LNPs
2/3/2021
Learn about measuring surface charge of an LNP-based mRNA vaccine for confirmation of LNP identity in a manufacturing setting, and stability assessment for process and formulation development.
-
Application Of Next Generation Analytical Tools For Vaccine Development
2/3/2021
In this webinar, we provide concise technical overviews of relevant platforms and specific examples of the roles automated analytical technologies play in the vaccine development workflow.